Guidelines for the management of community pneumonia in adult who needs hospitalization;Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital

Medicina Intensiva

Volumn 29, Issue 1, 2005, Pages 21-62

  Alvarez Rocha L ^a,d   Alos J I ^b   Blanquer, J ^c   Alvarez Lerma F ^b   Garau, J ^b   Guerrero, A ^b   Torres, A ^c   Cobo, J ^b   Jorda, R ^a   Menendez ^c   Olaechea, P ^a   Rodriguez De Castro F ^c  

^a SEMICYUC   (Spain)

^b SEIMC   (Spain)

^c Soc Espanola Neumologia C T   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Community acquired infection; Diagnosis; Etiology; Pharmacologic therapy; Pneumonia; Prevention

Indexed keywords

ACTIVATED PROTEIN C; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; DOBUTAMINE; DOPAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIPENEM; MACROLIDE; NITRIC OXIDE; NORADRENALIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; VASOACTIVE AGENT; VIRUS VACCINE;

ADRENAL INSUFFICIENCY; ADULT; ADULT DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN DETECTION; ARTICLE; ARTIFICIAL VENTILATION; ASPIRATION; ASPIRATION PNEUMONIA; BACTERIUM CULTURE; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; ENTEROBACTER; ENVIRONMENTAL EXPLOITATION; EVIDENCE BASED MEDICINE; FIBEROPTIC BRONCHOSCOPY; HEALTH CARE COST; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFLAMMATION; INTENSIVE CARE; LEGIONELLA PNEUMOPHILA; LUNG BIOPSY; LUNG LAVAGE; MEDICAL SOCIETY; MICROBIOLOGY; OCCUPATIONAL EXPOSURE; ORGANIZING PNEUMONIA; OXYGEN THERAPY; PATIENT POSITIONING; PENICILLIN RESISTANCE; PLEURA FLUID; PRACTICE GUIDELINE; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RADIOLOGY; RISK FACTOR; SEROLOGY; SMOKING CESSATION; SPAIN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; THORAX SURGERY;

EID: 20044385926     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-5691(05)74199-1     Document Type: Article

References (355)

1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
2. Graves EJ. Detailed diagnoses and procedures, national hospital discharge survey, 1990. Vital Health Stat 13 1992;1-225.
3. Marston BJ, Plouffe JF, File TM, Jr., Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157: 1709-18.
4. Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-63.
5. Monge V, San Martín VM, González A. The burden of community-acquired pneumonia in Spain. Eur J Public Health 2001;11:362-4.
6. Regidor E, Gutiérrez-Fisac JL, Calle ME, Otero AA. Mortality pattern in Spain, 1998. Med Clin (Barc.) 2002;118:13-5.
7. Research Committee of the British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-83: a survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;65:195-220.
8. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-36.
9. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51: 1010-6.
10. Dorca J, Bello S, Blanquer J, de Celis R, Molinos L, Torres A, et al. The diagnosis and treatment of community-acquired pneumonia. SEPAR. Sociedad Española de Neumología y Cirugía Torácica. Arch Bronconeumol 1997;33:240-6.
11. Álvarez LF, Cisneros JM, Fernández-Viladrich P, León C, Miro JM, Pachón J, et al. Indications for admission to the intensive care service of adult patients with severe infections. Enferm Infecc Microbiol Clin 1998;16:423-30.
12. Niederman MS, Bass JB, Jr., Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
13. Ewig S, Ruiz M, Mensa J, Marcos MA, Martínez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-8.
14. Gordon GS, Throop D, Berberian L. Validation of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients [abstract]. Am J Respir Crit Care Med 1996;153:A257.
15. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-88.
16. Munie M, Hueto J. Epidemiología de las neumonías adquiridas en la comunidad el Área de Salud I de Navarra. Med Clin (Bar) 1991;97:50-2.
17. Fekerty FR, Caldwel J, Gump D, Johnson JE, Maxson W, Mukholland J. Bacteria, Viruses and Mycoplasma in acute pneumoniae in adults. Am Rev Respir Dis 1971;104:499-507.
18. Ortqvist A, Sterner G, Nilsson JA. Severe community-acquired pneumonia: factors influencing need of intensive care treatment and prognosis. Scand J Infect Dis 1985;17:377-86.
19. Alkhayer M, Jenkins PF, Harrison BD. The outcome of community acquired pneumonia treated on the intensive care unit. Respir Med 1990:84:13-6.
20. Levy M, Dromer F, Brion N, Leturdu F, Carbon C. Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigations. Chest 1988;93: 43-8.
21. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989;11:586-99.
22. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994;96:313-20.
23. British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86:7-13.
24. Almirall J, Mesalles E, Klamburg J, Parra O, Agudo A. Prognostic factors of pneumonia requiring admission to the intensive care unit. Chest 1995;107:511-6.
25. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997;52:17-21.
26. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301.
27. Rello J, Rodríguez R, Jubert P, Álvarez B. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996;23:723-8.
28. Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001:33:158-65.
29. Torres A, Serra-Batlles J, Ferrer A, Jiménez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8.
30. Almirall J, González CA, Balanzo X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999;116:375-9.
31. Anderson JE, Jorenby DE, Scott WJ, Fiore MC. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002;121:932-41.
32. Farr BM, Bartlett CL, Wadsworth J, Miller DL. Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 2000;94:954-63.
33. Rosa H, Silverio AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol 2000;95:1290-3.
34. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923-9.
35. Agusti C, Rano A, Filella X, González J, Moreno A, Xaubel A, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003;123:488-98.
36. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344:665-71.
37. Black ER, Mushlin AI, Griner PF, Suchman AL, James RL, Jr., Schoch DR. Predicting the need for hospitalization of ambulatory patients with pneumonia. J Gen Intern Med 1991;6:394-400.
38. Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990;89:713-21.
39. Ruiz M, Ewig S, Marcos MA, Martínez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999;160:397-405.
40. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275: 134-41.
41. Álvarez B, Álvarez-Lerma F, Jordá R, Serra J, López-Cambra MJ, Sandar MD. Etíología y factores pronósticos de pacientes ingresados con neumonía comunitaria grave en España. Grupo de estudio de la neumonía comunitaria grave en España. Med Clin (Barc) 1998;111:650-4.
42. Ewig S, Schafer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000;16:1193-201.
43. Ewig S. Community-acquired pneumonia: epidemiology, risk, and prognosis. Eur Respir Mon 1997;3:13-35.
44. Georges H, Leroy O, Vandenbussche C, Guery B,Alfandari S, Tronchon L, et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med 1999;25:198-206.
45. Woodhead MA, Macfarlane JT, Rodgers FG, Laverick A, Pilkington R, Macrae AD. Aetiology and outcome of severe community-acquired pneumonia. J Infect 1985;10:204-10.
46. Riquelme R, Torres A, El Ebiary M, de la Bellacasa JP, Estruch R, Mensa J, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996;154:1450-5.
47. Fernández-Sola J, Junque A, Estruch R, Monforte R, Torres A, Urbano-Marquez A. High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med 1995;155:1649-54.
48. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342:681-9.
49. Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:25-8.
50. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001;163:1599-604.
51. El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163:645-51.
52. Ewig S, Torres A. Severe community-acquired pneumococcal pneumonia what might be done better. Intensive Care Med 1999;25:143-5.
53. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
54. Nelson S, Mason CM, Kolls J, Summer WR. Pathophysiology of pneumonia. Clin Chest Med 1995;16:1-12.
55. Ewig S, Bauer T, Hasper E, Pizzulli L, Kubini R, Luderitz B. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia, Eur Respir J 1995;8: 392-7.
56. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4.
57. Chien JW, Johnson JL. Viral pneumonias. Epidemic respiratory viruses. Postgrad Med 2000;107:41-2, 45-7, 51-2.
58. Ortqvist A, Hedlund J, Grillner L, Jalonen E, Kallings I, Leinonen M, et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur Respir J 1990;3:1105-13.
59. Leroy O, Devos P, Guery B, Georges H, Vandenbussche C, Coffinier C, et al. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs. Chest 1999;116:157-65.
60. Jong GM, Hsiue TR, Chen CR, Chang HY, Chen CW. Rapidly fatal outcome of bacteremic Klebsiella pneumoniae pneumonia in alcoholics. Chest 1995;107:214-7.
61. Woodhead MA, Radvan J, Macfarlane JT. Adult community-acquired staphylococcal pneumonia in the antibiotic era: a review of 61 cases. Q J Med 1987;64:783-90.
62. El Ebiary M, Sarmiento X, Torres A, Nogue S, Mesalles E, Bodi M, et al. Prognostic factors of severe Legionella pneumonia requiring admission to ICU. Am J Respir Crit Care Med 1997;156: 1467-72.
63. Leroy O, Georges H, Beuscart C, Guery B, Coffinier C, Vandenbussche C, et al. Severe community-acquired pneumonia in ICUs: prospective validation of a prognostic score. Intensive Care Med 1996;22:1307-14.
64. Olaechea PM, Quintana JM, Gallardo MS, Insausti J, Maravi E, Álvarez B. A predictive model for the treatment approach to community-acquired pneumonia in patients needing ICU admission. Intensive Care Med 1996;22:1294-300.
65. Potgieter PD, Hammond JM. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. Intensive Care Med 1996;22: 1301-6.
66. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336: 243-50.
67. Ewig S, Kleinfeld T, Bauer T, Seifert K, Schafer H, Goke N. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999; 14:370-5.
68. Atlas SJ, Benzer TI, Borowsky LH, Chang Y, Burnham DC, Metlay JP, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998;158:1350-6.
69. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-55.
70. Mylotte JM, Naughton B, Saludades C, Maszarovics Z. Validation and application of the pneumonia prognosis index to nursing home residents with pneumonia. J Am Geriatr Soc 1998;46: 1538-44.
71. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-7.
72. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000;55:219-23.
73. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82.
74. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-23.
75. Pascual FE, Matthay MA, Bacchetti P, Wachter RM. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000;117:503-12.
76. Mehta R, Groth M. Clinical application of a prognostic model for severe community-acquired pneumonia. Chest 2001; 119:312-3.
77. Blanquer J, Blanquer R, Borras R, Nauffal D, Morales P, Menendez R, et al. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991;46:508-11.
78. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-7.
79. Castro-Guardiola A, Armengou A, Garcia D, Viejo A, Obon M, García-Bragado F. Prospective study of 198 community acquired pneumonias in a general hospital. Enferm Infecc Microbiol Clin 1999;17:213-8.
80. Celis MR, Torres A, Zalacain R, Aspa J, Blanquer J, Blanquer R, et al. Diagnostic methods and treatment of community-acquired pneumonia in Spain: NACE study. Med Clin (Barc) 2002;119:321-6.
81. Fernández-Sabe N, Carratala J, Rosón B, Dorca J, Verdaguer R, Manresa F, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore) 2003;82:159-69.
82. Gómez J, Banos V, Ruiz GJ, Soto MC, Muñoz L, Núnez ML, et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1996;15:556-60.
83. Menéndez R, Córdoba J, de La CP, Cremades MJ, López-Hontagas JL, Salavert M, et al. Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med 1999;159:1868-73.
84. Rello J, Bodi M, Mariscal D, Navarro M, Díaz E, Gallego M, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003;123:174-80.
85. Ruiz-González A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med 1999;106:385-90.
86. Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J 2002;36 Suppl:20s-7.
87. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142:369-73.
88. Rello J, Quintana E, Ausina V, Net A, Prats G. A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993;103:232-5.
89. Akbar DH. Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta Diabetol 2001;38:77-82.
90. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58.
91. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:24-31.
92. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Chest 1994;105: 1487-95.
93. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542-8.
94. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur Respir J 2003;21:294-302.
95. Feldman C. Pneumonia in the elderly. Clin Chest Med 1999;20:563-73.
96. Torres A, Dorca J, Zalacain R, Bello S, El Ebiary M, Molinos L, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 1996;154:1456-61.
97. Soler N, Torres A, Ewig S, González J, Celis R, El Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157:1498-505.
98. LaForce FM, Mullane JF, Boehme RF, Kelly WJ, Huber GL. The effect of pulmonary edema on antibacterial defenses of the lung. J Lab Clin Med 1973;82:634-48.
99. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986; 146:2179-85.
100. Llorente JL, Zalacain R, Gaztelurrutia L, Talayero N, Antonana JM, Sobradillo V. Pneumonia in alcoholic patients: the clinical and etiological characteristics. Arch Bronconeumol 1994;30: 136-40.
101. Leroy O, Vandenbussche C, Coffinier C, Bosquet C, Georges H, Guery B, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997;156:1922-9.
102. Park DR, Sherbin VL, Goodman MS, Pacifico AD, Rubenfeld GD, Polissar NL, et al. The etiology of community-acquired pneumonia at an urban public hospital: influence of human immunodeficiency virus infection and initial severity of illness. J Infect Dis 2001;184:268-77.
103. Rimland D, Navin TR, Lennox JL, Jernigan JA, Kaplan J, Erdman D, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002;16:85-95.
104. Stuck AE, Minder CE, Frey FJ. Risk factors of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-63.
105. Clavo-Sánchez AJ, Girón-González JA, López-Prieto D, Canueto-Quintero J, Sánchez-Porto A, Vergara-Campos A, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997;24:1052-9.
106. Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42.
107. Castillo EM, Rickman LS, Brodine SK, Ledbetter EK, Kelly C. Streptococcus pneumoniae: bacteremia in an era of penicillin resistance. Am J Infect Control 2000;28:239-43.
108. Nava JM, Bella F, Garau J, Lite J, Morera MA, Martí C, et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis 1994;884-90.
109. Pallarés R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
110. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-7.
111. Aspa J, Rajas O, Rodríguez DC, Blanquer J, Zalacain R, Fenoll A, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004;38:787-98.
112. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin Clin Infect Dis 2000;31:1008-11.
113. Lynch III JP, Martínez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002;34 Suppl 1:S27-46.
114. Ho PL, Tse WS, Tsang KW, Kwok TK, Ng TK, Cheng VC, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-7.
115. Marston BJ. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994;154: 2417-22.
116. Plouffe JF. Importance of atypical pathogens of community-acquired pneumonia. Clin Infect Dis 2000;31 Suppl 2:S35-39.
117. Liam CK, Lim KH, Wong CM. Community-acquired pneumonia in patients requiring hospitalization. Respirology 2001;6:259-64.
118. Hatchette TF, Gupta R, Marrie T. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000:31: 1349-56.
119. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-5.
120. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003;138:109-18.
121. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997;157:1453-9.
122. Albaum MN, Hill LC, Murphy M, Li YH, Fuhrman CR, Button CA, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest 1996;110:343-50.
123. Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001;18:196-208.
124. Gharib AM, Stern EJ. Radiology of Pneumonia. Med Clin North Am 2001;85:1461-91.
125. Katz DS, Leung AN. Radiology of pneumonia. Clin Chest Med 1999;20:549-62.
126. Shah RM, Gupta S, Angeid-Backman E, O'Donnell J. Pneumococcal pneumonia in patients requiring hospitalization: effects of bacteremia and HIV seropositivity on radiographic appearance. Am J Roentgenol 2000;175:1533-6.
127. Tan MJ, Tan JS, Hamor RH, File TM, Jr., Breiman RF. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest 2000;117:398-403.
128. Young M, Marrie TJ. Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia. Arch Intern Med 1994;154:2729-32.
129. Menéndez R, Perpiñá M, Torres A. Evaluation of nonresolving and progressive pneumonia. Sem Respir Infect 2003; 18(2):103-11.
130. Rome L, Murali G, Lippmann M. Nonresolving pneumonia and mimics of pneumonia. Med Clin North Am 2001;85: 1511-30.
131. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27:358-63.
132. Kuru T, Lynch JP, III. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999;20:623-51.
133. Tomiyama N, Muller NL, Johkoh T, Honda O, Mihara N, Kozuka T, et al. Acute parenchymal lung disease in immunocompetent patients: diagnostic accuracy of high-resolution CT. AJR 2000;174:1745-50.
134. Gowardman J, Trent L. Severe community acquired pneumonia: a one-year analysis in a tertiary referral intensive care unit. N Z Med J 2000;113:161-4.
135. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
136. Ewig S, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care 2002;8:453-60.
137. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31:383-421.
138. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS. Schulz R, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278:32-9.
139. Skerrett SJ. Diagnostic testing for community-acquired pneumonia. Clin Chest Med 1999;20:531-48.
140. Gupta SK, Sarosi GA. The role of atypical pathogens in community-acquired pneumonia. Med Clin North Am 2001;85: 1349-65.
141. Juven T, Mertsola J, Toikka P, Virkki R, Leinonen M, Ruuskanen O. Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr Infect Dis J 2001;20:1028-33.
142. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56 Suppl 4:1-64.
143. Johanson WG, Seidenfeld JJ, Gomez P, De los Santos R, Coalson J. Bacteriologic diagnosis of nosocomial pneumonia following prolonged mechanical ventilation. Am Rev Respir Dis 1988;137:259-64.
144. Carroll KC. Laboratory diagnosis of lower respiratory tract infections: controversy and conudrums. J Clin Microbiol 2002;40:3115-20.
145. Cordero E, Pachón J, Rivero A, Girón-González JA, Gómez-Mateos J, Merino MD, et al. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002;21:362-7.
146. Ewig S, Schlochtermeier M, Goke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-92.
147. Bartlett RC. A plea for clinical relevance in medical microbiology. Am J Clin Pathol 1974;61:867-72.
148. Heineman HS, Chawla JK, Lofton WM. Misinformation from sputum cultures without microscopic examination. J Clin Microbiol 1977;6:518-27.
149. Bandyopadhyay T, Gerardi DA, Metersky ML. A comparison of induced and expectorated sputum for the microbiological diagnosis of community acquired pneumonia. Respiration 2000; 67:173-6.
150. Monro R, Neville S, Daley D, Mercer J. Microbiological aspects of an outbreak of Legionnaires' disease in south western Sydney. Pathology 1994;26:48-51.
151. Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004;169:342-7.
152. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
153. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001;14:181-6.
154. Michelow IC, Lozano J, Olsen K, Goto C, Rollins NK, Ghaffar F, et al. Diagnosis of Streptococcus pneumoniae lower respiratory infection in hospitalized children by culture, polimerase chain reaction, serological testing, and urinary antigen detection. Clin Infect Dis 2002;34:1-11.
155. Domínguez J, Galí N, Blanco S, Pedroso P, Prat C, Andreu F, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001;119:243-9.
156. Marcos MA, Jiménez de Anta MT, de la Bellacasa JP, González J, Martínez E, García E, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003;21:209-14.
157. Murdoch DR, Laing RT, Mills GD, Karalus NC, Town GI, Mirrett S, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-8.
158. Domínguez J, Galí N, Matas L, Pedroso P, Hernández A, Padilla E, et al. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples. Eur J Clin Microbiol Infect Dis 1999;18:896-8.
159. Formica N, Yates M, Beers M, Carnie J, Hogg G, Ryan N, et al. The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease. Epidemiol Infect. 2001;127:275-80.
160. Wever PC, Yzerman EP, Kuijper EJ, Speelman P, Dankert J. Rapid diagnosis of Legionnaires' disease using an immunochromatographic assay for Legionella pneumophila serogroup 1 antigen in urine during an outbreak in the Netherlands. J Clin Microbiol 2000;38:2738-9.
161. Domínguez JA, Gali N, Pedroso P, Fargas A, Padilla E, Manterola JM, et al. Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biotest urine antigen EIA for detection of Legionella antigen in both concentrated and nonconcentrated urine samples. J Clin Microbiol 1998;36: 2718-22.
162. Kazandjian D, Chiew R, Gilbert GL. Rapid diagnosis of Legionella pneumophila serogroup 1 infection with the Binax enzyme immunoassay urinary antigen test. J Clin Microbiol 1997; 35:954-6.
163. Kohler RB, Winn WC, Wheat LJ. Onset and duration of urinary antigen excretion in Legionnaires' disease. J Clin Microbiol 1984;20:605-7.
164. Saranglao A, Smith PR. Diagnostic tests for CAP: current approaches and future perspectives. Expert Rev Mol Diagn 2002; 2:329-36.
165. Smith PR. What diagnostic tests are needed for community-acquired pneumonia? Med Clin North Am 2001;85:1381-96.
166. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients: a 3-year prospective study in Japan. Chest 1998;114:1588-93.
167. Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle H. Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection. J Infect Dis 1990;162:1341-8.
168. Hindiyeh M, Hillyard DR, Carroll KC. Evaluation of the Prodesse Hexaplex Multiplex PCR assay for direct detection of seven respiratory viruses in clinical specimens. Am J Clin Pathol 2001;116:218-24.
169. McAvin JC, Reilly PA, Roudabush RM, Barnes WJ, Salmen A, Jackson GW, et al. Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR. J Clin Microbiol 2001;39:3446-51.
170. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features diagnosis and treatment. Clin Infect Dis 1995;21:S244-52.
171. Lorente ML, Falguera M, Nogues A, González AR, Merino MT, Caballero MR. Diagnosis of pneumococcal pneumonia by polymerase chain reaction (PCR) in whole blood: a prospective clinical study. Thorax 2000;55:133-7.
172. Cloud JL, Carroll KC, Pixton P, Erali M, Hillyard DR. Detection of Legionella species in respiratory specimens using PCR with sequencing confirmation. J Clin Microbiol 2000;5: 1709-12.
173. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
174. Socan M, Kese D, Marinic-Fiser N. Polymerase chain reaction for detection of Legionellae DNA in urine samples from patients with community-acquired pneumonia. Folia Microbiol (Praha) 2000;45:469-72.
175. Ostergaard L, Andersen PL. Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest 1993;104:1400-7.
176. Dorca J, Manresa F, Esteban L, Barreiro B, Prats E, Ariza J, et al. Efficacy, safety and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia. Am J Respir Crit Care Med 1995;151:1491-6.
177. García A, Roson B, Pérez JL, Verdaguer R, Dorca J, Carratala J, et al. Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia. J Clin Microbiol 1999; 37:709-14.
178. Ishida T, Hashimoto T, Arita M, Osawa M, Tachibana H, Nishioka M, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med 2001;40:873-7.
179. Vuori-Holopainen E, Salo E, Saxen H, Hedman K, Hyypia T, Lahdenpera R, et al. Etiological diagnosis of childhood pneumonia by use of transthoracic needle aspiration and modern microbiological methods. Clin Infect Dis 2002;34:583-90.
180. Zalacain R, Llorente JI, Gaztelurrutia L, Pijoan JI, Sobradillo V. Influence of three factors on the diagnostic effectiveness of transthoracic needle aspiration in pneumonia. Chest 1995;107: 96-100.
181. Hayes DA, McCarthy LC, Friedman M. Evaluation of two bronchofiberscopic methods of culturing the lower respiratory tract. Am Rev Respir Dis 1980;122:319-23.
182. Jordan GW, Wong GA, Hoeprich PD. Bacteriology of the lower respiratory tract as determined by fiber-optic bronchoscopy and transtracheal aspiration. J Infect Dis 1976;134:428-35.
183. Glaville AR, Marlin GE, Hartnett BJS, Yap JM, Bradbury R. The use of fiberoptic bronchoscopy with sterile catheter in the diagnosis of pneumonia. Aust NZJ Med 1985;15:309-19.
184. Pollock HM, Hawkins EL, Bonner JR, Sparkman T, Bass JB Jr. Diagnosis of bacterial pulmonary infections with quantitative protected catheter cultures obtained during bronchoscopy. J Clin Microbiol 1983;17:255-9.
185. Potgieter PD, Hammond JMJ. Etiology and diagnosis of pneumonia requiring ICU admision. Chest 1992;101:199-203.
186. Ruiz M, Torres A, Ewig S, Marcos MA, Alcón A, Lledo R, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 2000;162:119-25.
187. Shelhamer JH, Gill VJ, Quinn TC, Crawford SW, Kovacs JA, Masur H, et al. The laboratory evaluation of opportunistic pulmonary infections. Ann Intern Med 1996;124:585-99.
188. Feinsilver SH, Fein AM, Niederman MS, Schultz DE, Faegenburg DH. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest 1990;98:1322-6.
189. Dunn IJ, Marrie TJ, MacKeen AD, Bhan V, Janigan DT. The value of open lung biopsy in immunocompetent patients with community-acquired pneumonia requiring hospitalization. Chest 1994;106:23-7.
190. Dantzker DR. Gas exchange in the adult respiratory distress syndrome. Clin Chest Med 1982;3:57-67.
191. Bott J, Carroll MP, Conway JH, Keilty SE, Ward EM, Brown AM, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 1993;341:1555-7.
192. Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995;333: 817-22.
193. Confalonieri M, Potena A, Carbone G, Porta RD, Tolley EA, Umberto MG. Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am J Respir Crit Care Med 1999;160:1585-91.
194. Martin TJ, Hovis JD, Costantino JP, Bierman MI, Donahoe MP, Rogers RM, et al. A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. Am J Respir Crit Care Med 2000;161:807-13.
195. Ferrer M, Esquinas A, León M, González G, Alarcón A, Torres A. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003;168:1438-44.
196. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001;163:283-91.
197. Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338:347-54.
198. Remolina C, Khan AU, Santiago TV, Edelman NH. Positional hypoxemia in unilateral lung disease. N Engl J Med 1981; 304:523-5.
199. Lamm WJ, Graham MM, Albert RK. Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med 1994;150:184-93.
200. Pappert D, Rossaint R, Slama K, Gruning T, Falke KJ. Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest 1994;106:1511-6.
201. Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345:568-73.
202. Slutsky AS. The acute respiratory distress syndrome, mechanical ventilation, and the prone position. N Engl J Med 2001; 345:610-2.
203. Vincent JL. Hemodynamic support in septic shock. Intensive Care Med 2001;27 Suppl 1:S80-92.
204. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 2004;30:536-55
205. Patel GP, Gurka DP, Balk RA. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 2003;9:390-6.
206. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
207. Weil MH, Afifi AA. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock). Circulation 1970;41:989-1001.
208. Vincent JL, Dufaye P, Berre J, Leeman M, Degaute JP, Kahn RJ. Serial lactate determinations during circulatory shock. Crit Care Med 1983;11:449-51.
209. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-17.
210. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
211. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003;348:727-34.
212. Burry LD, Wax RS. Role of corticosteroids in septic shock. Ann Pharmacother 2004;38:464-72.
213. Katus HA, Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 2001;56:121-5.
214. Maus U, Rosseau S, Knies U. Seeger W, Lohmeyer J. Expression of pro-inflammatory cytokines by flow-sorted alveolar macrophages in severe pneumonia. Eur Respir J 1998;11:534-41.
215. de Gans J, van de BD. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002;347:1549-56.
216. Monton C, Torres A, El Ebiary M, Filella X, Xaubet A, de la Hellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999;27:1745-53.
217. Moore TA, Standiford TJ. Cytokine immunotherapy during bacterial pneumonia: from benchtop to bedside. Semin Respir Infect 2001;16:27-37.
218. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119:4198-25.
219. Nelson S, Bagby GJ, Dale D. Cytokine treatment of bacterial pneumonia. Semin Respir Infect 2001;16:38-46.
220. Restrepo MI, Jorgensen JH, Mortensen EM, Anzueto A. Severe community-acquired pneumonia: current outcomes, epidemiology, etiology, and therapy. Curr Opin Infect Dis 2001;14: 703-9.
221. Skerrett SJ, Park DR. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect 2001;16:76-84.
222. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323:1451-7.
223. MacFadden DK, Edelson JD, Hyland RH, Rodríguez CH, Inouye T, Rebuck AS. Corticosteroids as adjunctive therapy in treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987;1:1477-9.
224. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 2000; 31:1507-11.
225. Abraham E, Evans T. Corticosteroids and septic shock. JAMA 2002;288:886-7.
226. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest 1993;104:389-92.
227. Van SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915-22.
228. Matthay MA. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001;344:759-62.
229. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, López-Rodríguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
230. Ely EW, Bernard GR, Vincent JL. Activated protein C for severe sepsis. N Engl J Med 2002;347:1035-6.
231. Wenzel RP. Treating sepsis. N Engl J Med 2002;347: 966-7.
232. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002;347:1027-30.
233. Rello J, Catalán M, Díaz E, Bodi M, Álvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002;28:1030-5.
234. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization. Arch Intern Med 2002;162:682-8.
235. Gacouin A, Le Tulzo Y, La voue S, Camus C, Hoff J, Bassen R, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002;28:686-91.
236. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996;15:286-90.
237. Doern GV. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit. Diagn Microbiol Infect Dis 1995; 22:13-17.
238. Parrish AG. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. S Afr Med J 1998;88:1046-8;author reply 1050-1.
239. Wessels F, Anderson AN, Ebrahim O. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis. S Afr Med J 1998;88:251-5.
240. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993;31 Suppl E:171-6.
241. Stamler DA, Edelstein MA, Edelstein PH. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother 1994;38:217-22.
242. Edelstein PH. Review of azithromycin activity against Legionella spp. Pathol Biol (Paris) 1995;43:569-72.
243. Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001;32 Suppl 1:S64-S71.
244. Edelstein PH, Edelstein MA, Ren J, Polzer R, Gladue RP. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996;40: 314-9.
245. Edelstein PH, Higa F, Edelstein MA. In vitro activity of ABT-773 against Legionella pneumophila, its pharmacokinetics in guinea pigs, and its use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:2685-90.
246. Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:2204-9.
247. Dubois I, St Pierre C. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. J Antimicrob Chemother 2000;45 Suppl 1:41-6.
248. Charles L, Segreti J. Choosing the right macrolide antibiotic. A guide to selection. Drugs 1997;53:349-57.
249. Stout JE, Yu VL. Legionellosis. N Engl J Med 1997;337: 682-87.
250. Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001;61:443-98.
251. Zhanel GG. Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection. Curr Infect Dis Rep 2001;3:29-34.
252. Goldstein EJ, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002;35:1505-11.
253. Williams JH, Jr. Fluoroquinolones for respiratory infections: too valuable to overuse. Chest 2001;120:1771-5.
254. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002;22:1216-25.
255. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-60.
256. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-54.
257. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995;14:885-90.
258. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
259. Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.
260. Roson B, Carratala J, Tubau F, Dorca J, Linares J, Pallares R, et al. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001;7:85-96.
261. Tan TQ, Mason EO, Jr., Kaplan SL. Systemic infections due to Streptococcus pneumoniae relatively resistant to penicillin in a children's hospital: clinical management and outcome. Pediatrics 1992;90:928-33.
262. Watanabe H, Sato S, Kawakami K, Watanabe K, Oishi K, Rikitomi N, et al. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology 2000;5:59-64.
263. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
264. Barcenilla F, Gasco E, Rello J, Álvarez-Rocha L. Anti-bacterial treatment of invasive mechanical ventilation-associated pneumonia. Drugs Aging 2001;18:189-200.
265. Metha RM, Niederman MS. Nosocomial Pneumonia in the Intensive Care Unit: Controversies and Dilemmas. J Intensive Care Med 2003;18:175-88.
266. Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000;31:869-74.
267. Fraser DW, Tsai TR, Orenstein W, Parkin WE, Beecham HJ, Sharrar RG, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977;297:1189-97.
268. Dedicoat M, Venkatesan P. The treatment of Legionnaires' disease. J Antimicrob Chemother 1999;43:747-52.
269. Langtry HD, Brogden RN. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997;53:973-1004.
270. Edelstein PH. Legionnaires' disease. N Engl J Med 1998; 338:200-1.
271. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995;39:1661-6.
272. Schulin T, Wennersten CB, Ferraro MJ, Moellering RC, Jr., Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998;42: 1520-3.
273. Edelstein PH. Antimicrobial chemotherapy for legionnaires' disease: a review. Clin Infect Dis 1995;21 Suppl 3:S265-76.
274. Bebear C, Bouanchaud DH. A review of the in-vitro activity of quinupristin/dalfopristin against intracellular pathogens and mycoplasmas. J Antimicrob Chemother 1997;39 Suppl A:59-62.
275. Edelstein PH, Edelstein MA. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999;43:90-5.
276. Baltch AL, Smith RP, Franke MA, Michelsen PB. Anti-bacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998;42:3153-6.
277. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003;51:1119-29.
278. Sabria M, Campins M. Legionnaires' disease: update on epidemiology and management options. Am J Respir Med 2003; 2:235-43.
279. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9.
280. Pérez-Trallero E, Fernández-Mazarrasa C, García-Rey C, Bouza E, Aguilar L, García-de-Lomas J, et al. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334-40.
281. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
282. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;34 Suppl 1:S17-S26.
283. Bryan CS. Treatment of pneumococcal pneumonia: the case for penicillin G. Am J Med 1999;107:63S-8.
284. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa DE, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64.
285. Fogarty CM, Greenberg RN, Dunbar L, Player R, Marrie TJ, Kojak CM, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther 2001;23:425-39.
286. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000;118:1839-40.
287. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346: 747-50.
288. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
289. Zhanel GG, Hoban DJ, Chan CK. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-7.
290. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999;341:233-9.
291. Jones RN, Mutnick AH, Varnam DJ. Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: report from the SENTRY antimicrobial surveillance program (1997 to 2001). J Clin Microbiol 2002;40:4332-3.
292. Appelbaum PC. Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis 2002;34: 1613-20.
293. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis 2002;2:404-15.
294. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, García E, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
295. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
296. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003;123:1503-11.
297. Sánchez F, Mensa J, Martínez JA, García E, Marco F, González J, et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 2003;36:1239-45.
298. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032-9.
299. Ramírez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273-6.
300. Ramirez JA. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia. Ann Pharmacother 1998;32:S22-6.
301. Ramírez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-54.
302. Ramírez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001;161:848-50.
303. Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weinganen SR. The clinical benefit of in-hospital observation in "low-risk" pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998;113:142-6.
304. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-71.
305. Weingarten SR, Riedinger MS, Hobson P, Noah MS, Johnson B, Giugliano G, et al. Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996;153:1110-5.
306. Ramírez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995;2:327-33.
307. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001;161:722-7.
308. Fein AM, Feinsilver SH, Niederman MS. Nonresolving and slowly resolving pneumonia. Diagnosis and management in the elderly patient. Clin Chest Med 1993;14:555-69.
309. Daifuku R, Movahhed H, Fotheringham N, Bear MB, Nelson S. Time to resolution of morbidity: an endpoint for assessing the clinical cure of community-acquired pneumonia. Respir Med 1996;90:587-92.
310. Ortqvist A, Kalin M, Lejdeborn L, Lundberg B. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia. Chest 1990;97:576-82.
311. Menéndez R, Torres A, Neumofail G. Predictor factors of empirical antimicrobial treatment failure in community-acquired pneumonia. Eur Respir J 2002;20:357S.
312. Oberholzer A, Oberholzer C, Moldawer LL. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit Care Med 2000;28:N3-12.
313. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003;168:476-80.
314. El-Solh AA, Aquilina AT, Dhillon RS, Ramadan F, Nowak P, Davies J. Impact of invasive strategy on management of antimicrobial treatment failure in institutionalized older people with severe pneumonia. Am J Respir Crit Care Med 2002;166: 1038-43.
315. Jacobs JA, De Brauwer EI, Ramsay G, Cobben NA, Wagenaar SS, van der Ven AJ, et al. Detection of non-infectious conditions mimicking pneumonia in the intensive care setting: usefulness of bronchoalveolar fluid cytology. Respir Med 1999;93: 571-8.
316. Feldman C, Viljoen E, Morar R, Richards G, Sawyer L, Goolam MA. Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology 2001;6:323-30.
317. de la Pena L, Izaguirre D, Aguirrebengoa K, Grande C, Montejo M. Varicella pneumonia in the adult: study of 22 cases. Enferm Infecc Microbiol Clin 2000;18:493-5.
318. Harger JH, Ernest JM, Thurnau GR, Moawad A, Momirova V, Landon MB, et al. Risk factors and outcome of Varicella-Zoster virus pneumonia in pregnant women. J Infect Dis 2002; 185:422-7.
319. Fernández JA, López P, Orozco D, Merino J. Clinical study of an outbreak of Legionnaire's disease in Alcoy, Southeastern Spain. Eur J Clin Microbiol Infect Dis 2002;21:729-35.
320. Larkin M. Physicians urged to help patients quit smoking. Lancet 2002;359:1041.
321. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-27.
322. Poland GA. If you could halve the mortality rate, would you do it? Clin Infect Dis 2002;35:378-80.
323. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002;15:1831-6.
324. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial. Lancet 2000;355:93-7.
325. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med 1997;102:55-60.
326. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999;44 Suppl B:23-9.
327. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-50.
328. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43.
329. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Jr., Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-5.
330. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54.
331. Bridges CB, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2002;51:1-31.
332. Gravenstein S, Davidson HE. Current strategies for management of influenza in the elderly population. Clin Infect Dis 2002;35:729-37.
333. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin Infect Dis 1998;26:1117-23.
334. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89: 184-94.
335. Riley ID, Tarr PI, Andrews M, Pfeiffer M, Howard R, Challands P, et al. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977;1:1338-41.
336. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6.
337. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493-500.
338. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997;103:281-90.
339. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351:399-403.
340. Simberkoff MS, Cross AP, Al Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-27.
341. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31.
342. Gable CB, Holzer SS, Engelhart L, Friedman RB, Smeltz F, Schroeder D, et al. Pneumococcal vaccine. Efficacy and associated cost savings. JAMA 1990;264:2910-5.
343. Fan BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995;155:2336-40.
344. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
345. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-77.
346. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000;1:1.
347. Puig-Barbera J, Belenguer VA, Goterris PM, Brines Benlliure MJ. Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis. Aten Primaria 2002;30:269-81.
348. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al.
349. Outbreak of pneumococcal pneumonia among unvaccinated residents of a nursing home-New Jersey, April 2001. MMWR 2001;50:707-10.
350. Hoge CW, Reichler MR, Dominguez EA, Bremer JC, Mastro TD, Hendricks KA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994;331:643-8.
351. Hedlund JU, Kalin ME, Ortqvist AB, Henrichsen J. Anti-body response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994;154:1961-5.
352. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
353. Bello S, Chacón E, Omeñaca M, Gascón M, Esteban A, Senar A, et al. Diagnóstico precoz de la neumonía por Mycoplasma pneumoniae mediante la detección de IgM: estudio de dos técnicas serológicas. Arch Bronconeumol 1993;29:373-8.
354. Edelstein PH. Laboratory diagnosis of infections caused by legionellae. Eur J Clin Microbiol 1987;6:4-10.
355. Waterer GW, Baselski VS, Wunderink RG. Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. Am J Med 2001;110:41-8.